Compounds that inhibit Mcl-1 protein


Ontology type: sgo:Patent     


Patent Info

DATE

2020-04-28T00:00

AUTHORS

HARRINGTON PAUL E , ASHTON KATE , BROWN SEAN P , KALLER MATTHEW R , KOHN TODD J , LANMAN BRIAN ALAN , LI KEXUE , LI YUNXIAO , LOW JONATHAN D , MINATTI ANA ELENA , PICKRELL ALEXANDER J , STEC MARKIAN M , TAYGERLY JOSHUA

ABSTRACT

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. More... »

Related SciGraph Publications

  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2008-12. BCL-2 family antagonists for cancer therapy in NATURE REVIEWS DRUG DISCOVERY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0305", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "HARRINGTON PAUL E", 
            "type": "Person"
          }, 
          {
            "name": "ASHTON KATE", 
            "type": "Person"
          }, 
          {
            "name": "BROWN SEAN P", 
            "type": "Person"
          }, 
          {
            "name": "KALLER MATTHEW R", 
            "type": "Person"
          }, 
          {
            "name": "KOHN TODD J", 
            "type": "Person"
          }, 
          {
            "name": "LANMAN BRIAN ALAN", 
            "type": "Person"
          }, 
          {
            "name": "LI KEXUE", 
            "type": "Person"
          }, 
          {
            "name": "LI YUNXIAO", 
            "type": "Person"
          }, 
          {
            "name": "LOW JONATHAN D", 
            "type": "Person"
          }, 
          {
            "name": "MINATTI ANA ELENA", 
            "type": "Person"
          }, 
          {
            "name": "PICKRELL ALEXANDER J", 
            "type": "Person"
          }, 
          {
            "name": "STEC MARKIAN M", 
            "type": "Person"
          }, 
          {
            "name": "TAYGERLY JOSHUA", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd2658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030857223", 
              "https://doi.org/10.1038/nrd2658"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2020-04-28T00:00", 
        "description": "

    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

    \n

    \"embedded
    \nor a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.\n

    ", "endDate": "2038-03-28", "id": "sg:patent.US-10632128-B2", "name": "Compounds that inhibit Mcl-1 protein", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.417886.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-10632128-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-09-02T16:21", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/patent/patent_22.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-10632128-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-10632128-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-10632128-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-10632128-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    82 TRIPLES      15 PREDICATES      18 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-10632128-B2 schema:about anzsrc-for:03
    2 anzsrc-for:0305
    3 schema:author Nc85e2644c87544e982307adf7af03029
    4 schema:citation sg:pub.10.1007/s00018-008-8637-6
    5 sg:pub.10.1038/nrd2658
    6 schema:datePublished 2020-04-28T00:00
    7 schema:description <p id="p-0001" num="0000">Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="44.45mm" wi="69.43mm" file="US10632128-20200428-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif" orientation="portrait" inline="no"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US10632128-20200428-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US10632128-20200428-C00001.MOL"/></attachments></chemistry><br/> or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. </p>
    8 schema:endDate 2038-03-28
    9 schema:name Compounds that inhibit Mcl-1 protein
    10 schema:recipient grid-institutes:grid.417886.4
    11 schema:sameAs https://app.dimensions.ai/details/patent/US-10632128-B2
    12 schema:sdDatePublished 2022-09-02T16:21
    13 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    14 schema:sdPublisher N1f26940314864379bc4eb34b0cb3c982
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset patents
    17 rdf:type sgo:Patent
    18 N02f67214db3b43e4804db9588ea3515e schema:name KALLER MATTHEW R
    19 rdf:type schema:Person
    20 N0c697cf99cd84c7794c687d270bc10bb rdf:first N1e796784551f405c8159d50e387340eb
    21 rdf:rest N4ad4911e831f4dc68f8b3dd0eb64e6e1
    22 N1c733267abe54a00a48cec0cd18c855b rdf:first Nb25132e754074f929db72d141a5c497a
    23 rdf:rest N0c697cf99cd84c7794c687d270bc10bb
    24 N1e796784551f405c8159d50e387340eb schema:name PICKRELL ALEXANDER J
    25 rdf:type schema:Person
    26 N1f26940314864379bc4eb34b0cb3c982 schema:name Springer Nature - SN SciGraph project
    27 rdf:type schema:Organization
    28 N2e9740d87e6d4f4f8c1250d9fe97d302 schema:name LANMAN BRIAN ALAN
    29 rdf:type schema:Person
    30 N3a9cd8e351f84bf58f05da4fe556da9e schema:name STEC MARKIAN M
    31 rdf:type schema:Person
    32 N3bf7c6d7551d46cfafdd93bb3cdd9879 rdf:first Nac84464466b54e4ea68f215077cfdfe5
    33 rdf:rest Na3cad58750fe49d1a376909a359eb24a
    34 N4ad4911e831f4dc68f8b3dd0eb64e6e1 rdf:first N3a9cd8e351f84bf58f05da4fe556da9e
    35 rdf:rest Ne827272d391646e2b2faba0d8bb1dc3d
    36 N5fd46dad2c7644f099a8ba8207896819 rdf:first N9af0d128b4cf4db8a57540bf19718b68
    37 rdf:rest N6271bbef37bd4438b4710e6cda8bfb8a
    38 N6271bbef37bd4438b4710e6cda8bfb8a rdf:first Na061cb8621b247c4b1a2ed7373dbf326
    39 rdf:rest Nf987d15e0ff541f298b6beb8971e6c37
    40 N758cc05d9e9b434fa5c3c71c2143c3b4 schema:name LOW JONATHAN D
    41 rdf:type schema:Person
    42 N7751ff700c2949d39c7f7f68dda187b5 rdf:first N2e9740d87e6d4f4f8c1250d9fe97d302
    43 rdf:rest Ne79b196117cf46e5a427dbec07d5d55f
    44 N9af0d128b4cf4db8a57540bf19718b68 schema:name ASHTON KATE
    45 rdf:type schema:Person
    46 Na061cb8621b247c4b1a2ed7373dbf326 schema:name BROWN SEAN P
    47 rdf:type schema:Person
    48 Na3cad58750fe49d1a376909a359eb24a rdf:first N758cc05d9e9b434fa5c3c71c2143c3b4
    49 rdf:rest N1c733267abe54a00a48cec0cd18c855b
    50 Nac303d80a019461eb10c76bab4b566a2 schema:name KOHN TODD J
    51 rdf:type schema:Person
    52 Nac84464466b54e4ea68f215077cfdfe5 schema:name LI YUNXIAO
    53 rdf:type schema:Person
    54 Nb25132e754074f929db72d141a5c497a schema:name MINATTI ANA ELENA
    55 rdf:type schema:Person
    56 Nbcbbfb057ea54e178d966a81d083721d schema:name TAYGERLY JOSHUA
    57 rdf:type schema:Person
    58 Nc85e2644c87544e982307adf7af03029 rdf:first Ndcbb7701e1184f69907df68066d64ced
    59 rdf:rest N5fd46dad2c7644f099a8ba8207896819
    60 Ndcbb7701e1184f69907df68066d64ced schema:name HARRINGTON PAUL E
    61 rdf:type schema:Person
    62 Ne79b196117cf46e5a427dbec07d5d55f rdf:first Nf63759dea1b6447a93e216be9d13f2bc
    63 rdf:rest N3bf7c6d7551d46cfafdd93bb3cdd9879
    64 Ne827272d391646e2b2faba0d8bb1dc3d rdf:first Nbcbbfb057ea54e178d966a81d083721d
    65 rdf:rest rdf:nil
    66 Nf63759dea1b6447a93e216be9d13f2bc schema:name LI KEXUE
    67 rdf:type schema:Person
    68 Nf987d15e0ff541f298b6beb8971e6c37 rdf:first N02f67214db3b43e4804db9588ea3515e
    69 rdf:rest Nfc4489ca92ee432d97ae5a5991bb354c
    70 Nfc4489ca92ee432d97ae5a5991bb354c rdf:first Nac303d80a019461eb10c76bab4b566a2
    71 rdf:rest N7751ff700c2949d39c7f7f68dda187b5
    72 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
    73 rdf:type schema:DefinedTerm
    74 anzsrc-for:0305 schema:inDefinedTermSet anzsrc-for:
    75 rdf:type schema:DefinedTerm
    76 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    77 https://doi.org/10.1007/s00018-008-8637-6
    78 rdf:type schema:CreativeWork
    79 sg:pub.10.1038/nrd2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030857223
    80 https://doi.org/10.1038/nrd2658
    81 rdf:type schema:CreativeWork
    82 grid-institutes:grid.417886.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...